Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest

被引：1
|
作者：
Reich, Kristian [1 ]
Simpson, Eric [2 ]
Langley, Richard [3 ]
Warren, Richard B. [4 ,5 ]
Costanzo, Antonio [6 ,7 ]
Saeki, Hidehisa [8 ]
Almgren, Peter [9 ]
Gjerum, Le [9 ]
Carlsson, Anna [9 ]
Gooderham, Melinda [10 ,11 ,12 ]
Pinter, Andreas [13 ]
Weller, Marjolein De Bruin [14 ]
Blauvelt, Andrew [15 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Translat Res Inflammatory Skin Dis, Hamburg, Germany
[2] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR USA
[3] Dalhousie Univ, Div Clin Dermatol & Cutaneous Sci, Halifax, NS, Canada
[4] Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester, England
[5] Univ Manchester, NIHR Biomed Res Ctr, Manchester, Lancs, England
[6] Humanitas Univ, Dept Biomed Sci, Dermatol Unit, Milan, Italy
[7] IRCSS Humanitas Res Hosp, Skin Pathol Lab, Milan, Italy
[8] Nippon Med Sch, Dept Dermatol, Tokyo, Japan
[9] LEO Pharm AS, Ballerup, Denmark
[10] SKiN Ctr Dermatol, Peterborough, ON, Canada
[11] Queens Univ, Dept Dermatol, Kingston, ON, Canada
[12] Prob Med Res, Waterloo, ON, Canada
[13] Goethe Univ Frankfurt Main, Dept Dermatol Venereol & Allergol, Frankfurt, Germany
[14] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands
[15] Oregon Med Res Ctr, Portland, OR USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷
关键词：
moderate-to-severe; tralokinumab; safety; adverse events;
D O I：
10.1093/bjd/ljac140.009
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
309
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Safety and Efficacy of Tralokinumab in Older Adults With Moderate-to-Severe Atopic Dermatitis
    Merola, Joseph F.
    Butler, Daniel C.
    Mark, Thomas
    Schneider, Shannon
    Kim, Yestle
    Abuabara, Katrina
    JAMA DERMATOLOGY, 2023, 159 (10) : 1119 - 1123
  • [2] Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice
    Schloesser, Anne R.
    Shareef, Madena
    Olydam, Jill
    Nijsten, Tamar E. C.
    Hijnen, Dirk Jan
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 48 (05) : 510 - 517
  • [3] Long-term safety and efficacy of tralokinumab in more than 1400 patients with moderate-to-severe atopic dermatitis treated for up to 42 months: an interim analysis of ECZTEND
    Blauvelt, Andrew
    Langley, Richard
    Simpson, Eric
    Warren, Richard B.
    Costanzo, Antonio
    Saeki, Hidehisa
    Fangel, Stine
    Lassota, Nathan
    Carlsson, Anna
    Toth, Darryl
    Tauber, Marie
    Pinter, Andreas
    Ameen, Mahreen
    Reich, Kristian
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (03) : E92 - E93
  • [4] Long-term safety and efficacy of tralokinumab in more than 1400 moderate-to-severe atopic dermatitis patients treated for up to 42 months: An interim analysis of ECZTEND
    Blauvelt, Andrew
    Langley, Richard
    Simpson, Eric
    Warren, Richard B.
    Costanzo, Antonio
    Saeki, Hidehisa
    Toth, Darryl
    Tauber, Marie
    Pinter, Andreas
    Ameen, Mahreen
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB181 - AB181
  • [5] A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults
    Pezzolo, Elena
    Sechi, Andrea
    Tartaglia, Jacopo
    Naldi, Luigi
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (03) : 255 - 266
  • [6] Effectiveness and safety of tralokinumab treatment for moderate-to-severe atopic dermatitis in real-world clinical practice in Japan
    Hagino, Teppei
    Onda, Marina
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    EUROPEAN JOURNAL OF DERMATOLOGY, 2024, 34 (05) : 525 - 532
  • [7] Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis
    Chovatiya, Raj
    Wollenberg, Andreas
    Ribero, Simone
    Saeki, Hidehisa
    Oland, Christian B.
    Steffensen, Louise A.
    Tindberg, Ann-Marie
    Thyssen, Jacob P.
    Blauvelt, Andrew
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II49 - II50
  • [8] Improvement of the head and neck regions with continuous tralokinumab treatment for up to 4 years in adults with moderate-to-severe atopic dermatitis
    Chovatiya, Raj
    Wollenberg, Andreas
    Ribero, Simone
    Saeki, Hidehisa
    Oland, Christian B.
    Steffensen, Louise A.
    Tindberg, Ann-Marie
    Thyssen, Jacob P.
    Blauvelt, Andrew
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [9] Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis
    Khattri, Saakshi
    Brunner, Patrick M.
    Garcet, Sandra
    Finney, Robert
    Cohen, Steven R.
    Oliva, Margeaux
    Dutt, Riana
    Fuentes-Duculan, Judilyn
    Zheng, Xiuzhong
    Li, Xuan
    Bonifacio, Kathleen M.
    Kunjravia, Norma
    Coats, Israel
    Cueto, Inna
    Gilleaudeau, Patricia
    Sullivan-Whalen, Mary
    Suarez-Farinas, Mayte
    Krueger, James G.
    Guttman-Yassky, Emma
    EXPERIMENTAL DERMATOLOGY, 2017, 26 (01) : 28 - 35
  • [10] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Zheng, Y.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 : 72 - 72
12345